People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Affinivax, Inc. | — | Biotechnology | Series D+ | $233.0M | $7.8B | 2017 |
| Genocea Biosciences, Inc. | — | Biotechnology | Series C | $153.6M | $3.0B | 2010 |
| Celestial Therapeutics Inc. | — | Biotechnology | Seed | $2.1M | $3.5M | 2024 |
GEORGE SIBER at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside GEORGE SIBER on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Asish Xavier | 1 | 18 |
| Ali Behbahani | 1 | 17 |
| LEON CHEN | 1 | 15 |
| Kevin Bitterman | 1 | 15 |
| William Clark | 1 | 12 |
| Michael Higgins | 1 | 9 |
| Simeon George | 1 | 8 |
| Robert More | 1 | 7 |
| Stephen Hoffman | 1 | 7 |
| Andrew Hack | 1 | 5 |
| Steven Altschuler | 1 | 5 |
| Katrine Bosley | 1 | 4 |
| ROBERT PAULL | 1 | 4 |
| STEVE HOFFMAN | 1 | 3 |
| Thomas Davis | 1 | 3 |
| Narinder Singh | 1 | 2 |
| Annelise Barron | 1 | 2 |
| Gisela Schwab | 1 | 2 |
| Frances Heller | 1 | 2 |
| Richard Malley | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.